Aclaris Therapeutics' bosakitug (ATI-045) missed the primary and secondary endpoints in the Phase 2 ADMIRATION trial in patients with moderate-to-severe atopic dermatitis. The study's primary endpoint measured the percentage change from baseline in Eczema Area and Severity Index score at week 24.
Bosakitug is a humanized monoclonal antibody targeting thymic stromal lymphopoietin, or TSLP, evaluated for efficacy and safety in the trial. Despite the endpoint misses, pharmacodynamic results showed target engagement of TSLP and downregulation of biomarkers associated with immune activation, including Th1, Th2 and Th17, while the treatment was generally well tolerated.
“We are disappointed that the ADMIRATION trial did not overcome the historical challenges of addressing atopic dermatitis with an anti-TSLP monoclonal antibody alone,” said Chief Executive Officer Neal Walker. Walker said the findings do not change the company's development priorities, which remain focused on oral kinase inhibitors and ATI-052, an anti-TSLP/IL-4Rα bispecific antibody.
Aclaris has initiated a Phase 2b trial of modzatinib, its oral ITK/JAK3 inhibitor, in lichen planus. The company has also completed investigational new drug application-enabling studies for ATI-9494, an oral ITK inhibitor, and expects to submit its application during the fourth quarter of 2026.
For ATI-052, Aclaris intends to initiate a Phase 2b trial in eosinophilic esophagitis in the first quarter of 2027. Walker said the company expects regulatory, clinical and data milestones across modzatinib, ATI-9494 and ATI-052 throughout 2027, as it continues development of its portfolio of product candidates for immuno-inflammatory diseases.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!